Supplementary Online Content


eAppendix. Determination of SPRINT Eligibility

This supplementary material has been provided by the authors to give readers additional information about their work.
eAppendix. Determination of SPRINT Eligibility

1. Applied exclusion criteria
   a. Age <50 years
   b. Patient report of prior stroke
   c. Patient report of heart failure
   d. Diabetes
   e. Dialysis
   f. Albuminuria defined using albumin:creatinine ratio >300 mg/g

2. Among those not excluded, the following inclusion criteria were applied
   a. At least one high risk condition
      i. ≥75 years
      ii. Prior coronary heart disease defined as report of myocardial infarction or angina or angina per Rose angina questionnaire
      iii. Estimated MDRD glomerular filtration rate ≥20 to 60 ml/min/1.73 m²
      iv. 10-year Framingham risk ≥15%
   b. Met BP and medication cutoffs
      i. Untreated SBP 130-180 mmHg on 0 or 1 medications
      ii. SBP 130-170 mmHg on 2 medications
      iii. SBP 130-160 on 3 medications
      iv. SBP 130-150 on 4 medications
Medication counts were defined as the number of different medication classes

Determination of HOPE Eligibility

1. Applied exclusion criteria
   a. Males <55 years, Females <65 years
   b. Diabetes
   c. Prior coronary heart disease defined as report of myocardial infarction or angina or angina per Rose angina questionnaire
   d. Prior stroke
   e. Indication for an ACE inhibitor or ARB or thiazide
      i. Report of heart failure
      ii. Currently taking an ACE, ARB, or thiazide
   f. Indication for a statin: applied modified ATPIII guidelines
      i. Calculation of ATP-III risk factors
         1. Smoking
         2. Hypertension, defined by blood pressure treatment or SBP \( \geq 140 \text{ mmHg} \) or DBP \( \geq 90 \text{ mmHg} \)
         3. Low HDL-C \(<40 \text{ mg/dL}\)
            a. High HDL-C \(\geq 60 \text{ mg/dL}\) considered a negative risk factor
         4. Impaired fasting glucose (A1c 5.7% to <6.5%)
         5. Age \(\geq 45 \text{ in males or age} \geq 55 \text{ in females}\)
ii. Estimation of ATP-III recommendations for non-HDL-C to those not excluded otherwise. As LDL-C was unavailable for the entire population we applied a modification of ATP-III guidelines based on non-HDL-C.

1. Non-HDL-C ≥220 mg/dL
2. Non-HDL ≥190 mg/dL and at least 2 risk factors and Framingham risk <10%
3. Non-HDL ≥160 mg/dL and at least 2 risk factors and Framingham risk ≥10%
4. Non-HDL ≥160 mg/dL and at least 2 risk factors and Framingham risk ≥20%

2. Among those not excluded, at least one inclusion
   a. Obesity, defined by BMI ≥30 kg/m²
   b. Current smoking
   c. Low HDL-C (<1 mmol/L in males, <1.3 mmol/L in females)
   d. Impaired fasting glucose (A1c >5.7, <6.5%)
   e. Albuminuria
   f. Estimated glomerular filtration rate (≥45 ml/min/1.73 m² to <60 ml/min/1.73 m²).